Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 1;34(6):32-39.
doi: 10.1097/01.JAA.0000735760.65235.3c.

Managing toxicities associated with immune checkpoint inhibitors

Jiyeon Joy Park  1 , Syed Arafath, Samir T Kumar, Roopali Sharma, Deepali Dixit
Affiliations

Managing toxicities associated with immune checkpoint inhibitors

Jiyeon Joy Park et al. JAAPA. .

Abstract

Recent development of immunotherapy has led to remarkable advancement in cancer therapy. Drugs that inhibit the cytotoxic T-lymphocyte-associated protein (CTLA-4) and programmed death-1 (PD-1) immune checkpoint pathways have shown improved patient survival. However, by altering the immune response to fight cancer, a new class of adverse reactions has emerged, known as immune-related adverse events. These adverse events are due to overactivation of the immune system in almost any organ of the body, can occur at any point in a patient's treatment course, and may become life-threatening. This article describes how to promptly recognize and manage these toxicities.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol . 2015;33(17):1889–1894.
    1. Zhang H, Chen J. Current status and future directions of cancer immunotherapy. J Cancer . 2018;9(10):1773–1781.
    1. Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer . 2017;5(1):95.
    1. Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol . 2017;28(suppl 4):iv119–iv142.
    1. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res . 2015;4(5):560–575.

MeSH terms

Substances

LinkOut - more resources